Novavax

$179.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$16.74 (+10.59%) Today
+$4.38 (+2.51%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Novavax and other stocks, options, and ETFs commission-free!

About NVAX

Novavax, Inc. Common Stock, also called Novavax, is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD. The listed name for NVAX is Novavax, Inc. Common Stock.

CEO
Stanley C. Erck
Employees
791
Headquarters
Gaithersburg, Maryland
Founded
1987
Market Cap
15.00B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
3.90M
High Today
$175.89
Low Today
$149.12
Open Price
$166.65
Volume
5.83M
52 Week High
$331.68
52 Week Low
$6.77

NVAX News

MarketWatchMar 5

Novavax Inc. stock rises Friday, outperforms market

Shares of Novavax Inc. NVAX, +10.59% jumped 10.59% to $174.84 Friday, on what proved to be an all-around great trading session for the stock market, with the NA
Yahoo FinanceMar 1

Novavax CEO on COVID-19 vaccine trial progress

Novavax CEO Stanley Erck joined Yahoo Finance Live to discuss the company's COVID-19 vaccine trial progress and his business outlook for the company. Video Tra
MarketWatchMar 1

Novavax posts wider quarterly loss, sales jump due to pandemic-related services

Shares of Novavax Inc. NVAX, +3.92% wavered between gains and losses in the extended session Monday after the biotech company reported a wider-than-expected fou

NVAX Earnings

-$3.21
-$1.56
$0.08
$1.73
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$1.49 per share
Actual
-$2.70 per share
Replay Earnings Call

You May Also Like

RDNT

More NVAX News

ReutersMar 1

Novavax COVID-19 shot could be cleared for U.S. use by May: CEO

(Reuters) - Novavax Inc’s chief executive said on Monday that its COVID-19 vaccine could be cleared for use in the United States as soon as May if U.S. regulato
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure